Australia to consider further regulation of complementary products

BMJ 2008; 336 doi: (Published 05 June 2008) Cite this as: BMJ 2008;336:1270
  1. Bob Burton
  1. 1Hobart

The Australian government is considering further regulation of the $A2bn (£970m; €1.2bn; $1.9bn) a year complementary medicines industry after a consumer group raised concerns that products are promoted despite a lack of independently assessed evidence on their effectiveness.

In May the Australian Consumers Association published a general overview of the studies of glucosamine to treat osteoarthritis. The association concluded that some glucosamine products were at best on a par with a placebo and at worst ineffective. Australian consumers are estimated to spend approximately $A49m on these supplements a year.

Symbion Health, a company …

View Full Text

Log in

Log in through your institution


* For online subscription